The Lancet: CoronaVac COVID-19 vaccine is safe and protects against disease, interim analysis

Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19.